Moderna has resolved a protracted legal battle by agreeing to a $950 million upfront settlement with Genevant and Arbutus Biopharma. This agreement effectively ends allegations that Moderna infringed on patents related to lipid nanoparticle (LNP) delivery technology—the critical mechanism used to transport mRNA safely into human cells—during the production of its Spikevax vaccine.
This strategic settlement grants Moderna a global, non-exclusive license to the LNP technology for infectious disease applications without the burden of future royalties. While the payout is substantial, market analysts view the deal favorably, noting that it eliminates a significant “tail risk” of much higher damages given Moderna’s $48 billion in cumulative vaccine sales. The resolution also includes mutual pledges to cease further litigation regarding specific patents and products.
Moderna’s leadership stated that resolving these legacy pandemic-era matters allows the firm to fully pivot toward its 2026 growth strategy. With the legal uncertainty removed, Moderna is focusing on its robust pipeline, including experimental COVID-influenza combination shots and RSV vaccines, aiming for a cash-positive position by 2028 and a return to revenue growth in the near term.